Amgen Inc AMGN:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD

After Hours: Last | 05/17/24 EDT

313.05

+0.58 (+0.19%)

Volume

107,618

312.47

-2.25 (-0.71%)

Volume

1,858,982

52 week range

211.71 - 329.72

Open315.28
Day High315.28
Day Low310.37
Prev Close314.72
52 Week High329.72
52 Week High Date02/05/24
52 Week Low211.71
52 Week Low Date06/01/23

Key Stats

Market Cap167.62B
Shares Out536.43M
10 Day Average Volume3.42M
Dividend9.00
Dividend Yield2.88%
Beta0.61
YTD % Change8.49

KEY STATS

Open315.28
Day High315.28
Day Low310.37
Prev Close314.72
52 Week High329.72
52 Week High Date02/05/24
52 Week Low211.71
52 Week Low Date06/01/23
Market Cap167.62B
Shares Out536.43M
10 Day Average Volume3.42M
Dividend9.00
Dividend Yield2.88%
Beta0.61
YTD % Change8.49

RATIOS/PROFITABILITY

EPS (TTM)7.00
P/E (TTM)44.65
Fwd P/E (NTM)16.11
EBITDA (TTM)11.625B
ROE (TTM)72.57%
Revenue (TTM)29.532B
Gross Margin (TTM)66.38%
Net Margin (TTM)12.74%
Debt To Equity (MRQ)1,274.79%

EVENTS

Earnings Date08/01/2024(est)
Ex Div Date05/16/2024
Div Amount2.25
Split Date-
Split Factor-

Latest On Amgen Inc

Trade Tracker: The Investment Committee details their latest portfolio movesMay 17, 2024CNBC.com
FDA approves Amgen's treatment for most deadly form of lung cancer May 16, 2024CNBC.com
Lilly falls on a rival's study — plus, we're removing 3 stocks from our watchlist May 16, 2024CNBC.com
Trade Tracker: Joe Terranova buys Amgen and MerckMay 15, 2024CNBC.com
Trade Tracker: Bill Baruch buys more Apple and AmgenMay 8, 2024CNBC.com

Content From Our Affiliates

Analysts Are Bullish on These Healthcare Stocks: Amgen (AMGN), Eli Lilly & Co (LLY)May 17, 2024TipRanks
U.S. FDA Approves Amgen’s (NASDAQ:AMGN) ImdelltraMay 17, 2024TipRanks
Balancing Early Approval and Market Challenges: Amgen’s Imdelltra Receives a Hold Rating from Carter GouldMay 16, 2024TipRanks
Amgen says FDA approves ImdelltraMay 16, 2024TipRanks
FDA grants accelerated approval for Amgen’s tarlatamab-dlleMay 16, 2024TipRanks

Profile

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin...

Robert Bradway

Chairman of the Board, President, Chief Executive Officer

Peter Griffith

Chief Financial Officer, Executive Vice President

David Reese

Executive Vice President, Chief Technology Officer

Murdo Gordon

Executive Vice President - Global Commercial Operations

Lori Johnston

Executive Vice President - Human Resources

Address

One Amgen Center Drive

Thousand Oaks, CA

91320

United States

https://www.amgen.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
PFE Pfizer Inc	28.64	-0.28	-0.97%
NVS Novartis AG	102.57	-0.12	-0.12%
SNY Sanofi SA	48.67	-0.15	-0.31%
GILD Gilead Sciences Inc	67.72	-0.14	-0.21%
RHHBY Roche Holding AG	32.81	+0.16	+0.49%